AMPLITUDE Trial Update: Niraparib Plus Abiraterone Shows Promise for HRR-Altered Metastatic Prostate Cancer

Positive Results From Phase 3 Trial of CAN-2409 for Localized Prostate Cancer Led to RMAT Designation